Today's Low
₹ 47.50
Today's High
₹ 48.70
52 Weeks Low
₹ 16.52
52 Weeks High
₹ 90.95
Lower
₹ 45.95
Upper
₹ 50.75
Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. Its product portfolio includes general formulations, which consists of general tablets, capsules, and dry syrups; and beta lactum formulations, which comprises penicillin and cephalosporin range of formulations in tablets, capsules, and dry syrups. The company was founded on March 18, 1994 and is headquartered in Thane, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 66.2 | 59.0 | 58.5 | 56.6 | 59.2 | 45.7 | 38.2 | 36.8 | 26.2 | 23.3 | 13.7 | 7.2 |
Total Non-Current Assets | 22.9 | 19.7 | 17.1 | 18.6 | 17.1 | 13.7 | 10.3 | 8.7 | 9.5 | 7.9 | 4.7 | 3.2 |
Total Assets | 89.1 | 78.7 | 75.6 | 75.3 | 76.3 | 59.4 | 48.4 | 45.5 | 35.7 | 31.2 | 18.3 | 10.4 |
Total Current Liabilities | 43.2 | 39.6 | 38.0 | 40.5 | 45.5 | 30.2 | 21.1 | 26.4 | 21.5 | 22.0 | 12.7 | 3.5 |
Total Non-Current Liabilities | 2.1 | 2.5 | 5.2 | 4.9 | 2.6 | 2.6 | 10.9 | 4.4 | 0.6 | 0.7 | 0.6 | 3.1 |
Shareholder's Funds | 43.8 | 36.6 | 32.5 | 29.9 | 28.2 | 26.7 | 16.4 | 14.7 | 13.6 | 8.6 | 5.1 | 3.8 |
Total Liabilities | 89.1 | 78.7 | 75.6 | 75.3 | 76.3 | 59.4 | 48.4 | 45.5 | 35.7 | 31.2 | 18.3 | 10.4 |
The Industry Quick Ratio stands at 1.77, vs the Quick Ratio of 1.08, which results in a Negative aspect.
The Industry Price to BV stands at 6.01, vs the Price to BV of 8.11, which results in a Positive aspect.
The Industry Current Ratio stands at 2.53, vs the Current Ratio of 1.53, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.20, vs the Debt to Equity Ratio of 0.18, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2010 | FY 2009 | FY 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 140.4 | 121.0 | 122.4 | 88.6 | 97.7 | 61.0 | 54.4 | 66.7 | 51.0 | 44.9 | 33.7 | 11.9 | 12.6 | 10.9 |
Total Expenditure | 131.0 | 113.7 | 117.2 | 85.8 | 94.9 | 57.5 | 50.4 | 63.0 | 48.1 | 42.7 | 32.3 | 10.9 | 11.8 | 10.4 |
Operating Profit(Excl OI) | 13.6 | 9.4 | 6.3 | 4.9 | 4.7 | 4.4 | 4.4 | 3.9 | 3.0 | 2.3 | 1.5 | 1.0 | 0.8 | 0.5 |
Add: Other Income | 4.1 | 2.0 | 1.0 | 2.1 | 1.9 | 0.9 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Operating Profit | 13.6 | 9.4 | 6.3 | 4.9 | 4.7 | 4.4 | 4.4 | 3.9 | 3.0 | 2.3 | 1.5 | 1.0 | 0.8 | 0.5 |
Less: Interest | 0.8 | 0.7 | 0.9 | 1.1 | 1.0 | 1.5 | 1.3 | 0.9 | 0.8 | 0.6 | 0.4 | 0.3 | 0.2 | 0.0 |
PBDT | 12.8 | 8.7 | 5.4 | 3.9 | 3.7 | 2.9 | 3.0 | 3.1 | 2.2 | 1.7 | 1.1 | 0.7 | 0.6 | 0.5 |
Less: Depreciation Amortization | 2.7 | 2.2 | 1.7 | 1.7 | 1.5 | 1.0 | 1.1 | 1.2 | 1.1 | 0.8 | 0.4 | 0.3 | 0.3 | 0.3 |
PBT & Exceptional Items | 10.1 | 6.5 | 3.7 | 2.2 | 2.2 | 1.9 | 2.0 | 1.9 | 1.1 | 1.0 | 0.7 | 0.3 | 0.3 | 0.2 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 10.1 | 6.5 | 3.7 | 2.2 | 2.2 | 1.9 | 1.7 | 1.9 | 1.1 | 1.0 | 0.7 | 0.3 | 0.3 | 0.2 |
Less: Taxation | 2.9 | 1.7 | 1.1 | 0.6 | 0.6 | 0.7 | 0.1 | 0.7 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 |
Profit After Tax | 7.2 | 4.8 | 2.6 | 1.6 | 1.6 | 1.2 | 1.6 | 1.1 | 0.8 | 0.6 | 0.4 | 0.2 | 0.1 | 0.1 |
Earnings Per Share | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PE Ratio stands at 42.40, vs the PE Ratio of 57.13, which results in a Positive aspect.
The Industry PAT Margin stands at 9.68, vs the PAT Margin of 5.16, which results in a Negative aspect.
The Industry PAT Growth stands at 41.10, vs the PAT Growth of 50.49, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 10.1 | 6.5 | 3.7 | 2.2 | 2.2 | 1.9 | 1.7 | 1.9 | 1.1 | 1.0 | 0.7 |
Tax Paid | -2.5 | -1.8 | -0.9 | -0.5 | -0.5 | -0.6 | -0.5 | -0.6 | -0.4 | -0.3 | -0.6 |
Adjustment | 2.7 | 2.5 | 2.6 | 2.1 | 1.9 | 2.2 | 2.5 | 1.9 | 1.8 | 1.2 | 0.8 |
Changes In Working Capital | 10.1 | 6.5 | 3.7 | 2.2 | 2.2 | 1.9 | 1.7 | 1.9 | 1.1 | 1.0 | 0.7 |
Cash Flow after changes in Working Capital | 10.7 | 7.7 | -10.4 | 1.5 | 5.5 | 5.7 | -2.4 | -3.1 | 0.1 | 3.0 | 2.6 |
Cash Flow from Operating Activities | 8.2 | 5.9 | -11.3 | 1.0 | 4.9 | 5.1 | -3.2 | -3.7 | -0.3 | 2.7 | 2.1 |
Cash Flow from Investing Activities | -6.6 | -1.8 | -17.0 | -3.1 | -4.4 | -5.0 | -2.8 | 0.3 | -2.2 | -3.9 | -1.6 |
Cash Flow from Financing Activities | -1.8 | -5.8 | 18.3 | 2.6 | -0.6 | -0.6 | 5.8 | 2.2 | 3.0 | 2.3 | -0.5 |
Net Cash Inflow / Outflow | -0.3 | -1.7 | -10.0 | 0.5 | 0.0 | -0.5 | -0.2 | -1.2 | 0.5 | 1.1 | 0.0 |
Opening Cash & Cash Equivalents | 1.2 | 2.8 | 0.0 | 0.2 | 0.2 | 0.7 | 0.7 | 1.8 | 1.3 | 0.2 | 0.2 |
Closing Cash & Cash Equivalent | 0.9 | 1.2 | -10.0 | 0.6 | 0.2 | 0.2 | 0.4 | 0.7 | 1.8 | 1.3 | 0.2 |
The Industry PFCF Ratio stands at 37.73, vs the PFCF Ratio of 507.57, which results in a Positive aspect.
The Industry PCF RATIO stands at 27.04, vs the PCF RATIO of 75.90, which results in a Positive aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
---|---|---|---|---|---|---|---|
Net Sales | 297.7 | 423.6 | 314.7 | 279.9 | 388.5 | 404.6 | 331.4 |
Total Income | 300.5 | 433.1 | 317.8 | 280.3 | 397.1 | 420.1 | 347.3 |
Total Expenditure | 270.4 | 392.8 | 290.1 | 248.3 | 354.6 | 373.2 | 333.2 |
PBIDT (Excl OI) | 27.3 | 30.8 | 24.6 | 31.6 | 33.9 | 31.5 | -1.8 |
Other Income | 2.7 | 9.6 | 3.1 | 0.4 | 8.6 | 15.5 | 16.0 |
Operating Profit | 30.1 | 40.3 | 27.7 | 32.1 | 42.5 | 47.0 | 14.1 |
Interest | 2.2 | 1.8 | 1.7 | 2.1 | 2.0 | 1.7 | 1.7 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 27.8 | 38.5 | 26.0 | 30.0 | 40.5 | 45.2 | 12.4 |
Depreciation | 7.2 | 7.1 | 7.1 | 7.3 | 7.4 | 6.6 | 5.9 |
Profit Before Tax | 20.6 | 31.4 | 18.8 | 22.7 | 33.2 | 38.6 | 6.5 |
Tax | 6.2 | 7.2 | 5.6 | 5.1 | 10.7 | 9.9 | 2.9 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 14.5 | 24.3 | 13.2 | 17.7 | 22.5 | 28.7 | 3.6 |
Net Profit | 14.5 | 24.3 | 13.2 | 17.7 | 22.5 | 28.7 | 3.6 |
ADDITIONAL INFOS: | |||||||
Equity Capital | 166.0 | 166.0 | 166.0 | 166.0 | 166.0 | 166.0 | 166.0 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 0.2 | 0.3 | 0.2 | 0.2 | 1.4 | 1.7 | 0.2 |
Operating Profit Margin | 10.1 | 9.5 | 8.8 | 11.5 | 10.9 | 11.6 | 4.3 |
Net Profit Margin | 4.9 | 5.7 | 4.2 | 6.3 | 5.8 | 7.1 | 1.1 |
The Industry Net Sales Growth stands at 10.00, vs the Net Sales Growth of 16.04, which results in a Positive aspect.
The Industry Mcap Growth stands at -4.23, vs the Mcap Growth of 344.64, which results in a Positive aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 53.90 | 56.44 | 49.77 |
R3 | 52.27 | 52.48 | 48.98 |
R2 | 50.63 | 50.74 | 48.72 |
R1 | 49.42 | 49.63 | 48.46 |
Pivot | 47.78 | 47.89 | 47.78 |
S1 | 46.57 | 46.78 | 47.94 |
S2 | 44.93 | 45.04 | 47.68 |
S3 | 43.72 | 43.93 | 47.42 |
S4 | 42.50 | 39.34 | 46.63 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
90.11
Bearish
RSI
24.81
Bullish
ROC
-1.24
Bearish
UltimateOscillator
56.12
Neutral
Williams Indicator
-50.79
Neutral
CCI Indicator
-39.38
Neutral
MACD
-2,882.16
Bearish
Stochastic Indicator
51.73
Neutral
ATR
3.61
High Volatility
Ex-Date | Ratio | Record Date |
---|---|---|
16-11-2021 | 3:1 | 17-11-2021 |
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
12-02-2024 | Quarterly Results |
09-11-2023 | Quarterly Results |
10-08-2023 | Quarterly Results |
11-05-2023 | Audited Results |
10-02-2023 | Quarterly Results |
02-02-2023 | Stock Split |
12-11-2022 | Quarterly Results |
12-08-2022 | Quarterly Results |
20-05-2022 | Audited Results |
12-11-2021 | Half Yearly Results |
07-10-2021 | Increase in Authorised Capital & Bonus issue Inter alia, to transact the following business: 1. To consider increase in authorized share capital of the Company and subsequent alteration to the Memorandum of Association of the Company; 2. To recommend and approve issue of Bonus shares to the equity shareholders of the Company; 3. To approve the proposal of Migration of Company from SME platform of BSE to Main Board of BSE Limited as well as on the Main Board of NSE Limited; 4. To approve the transactions to be entered into with the related parties of the Company; and 5. Any other business with the permission of the Chair. |
27-05-2021 | Audited Results |